Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by 90guppyon Apr 29, 2020 11:32am
91 Views
Post# 30966437

RE:Big Pharma Shopping for.....

RE:Big Pharma Shopping for.....That's right big pharma does not innovate that much, they buy out small research companies who are willing to take the initial research risks.  That's the playbook of big pharma in minimizing the risk. They have the money so why not just buy rights from small companies.

https://endpts.com/full-steam-ahead-pfizer-goes-bargain-hunting-in-an-age-of-coronavirus-with-a-special-focus-on-cancer-and-rare-diseases/

https://www.pharmaceutical-technology.com/news/merck-buys-calporta-therapeutics/

https://www.fiercebiotech.com/biotech/merck-slower-than-its-peers-edges-into-covid-19-fight

silentrunning wrote: .......it would appear someone like LottoVXL? From Endpoints: 4.Bioregnum: Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus with a special focus on cancer and rare diseases byJOHN CARROLL Pfizer made a splash this week with its plans to spend $500 million on Covid-19 research. But the pharma giant isnt letting a pandemic interfere with the M&A it needs to fulfill its longterm mission. In fact, the outbreak may even lend them a hand in finding clinical-stage assets for the pipeline if only the biotech execs and boards they approach fully understand the position theyre in. Pfizer CFO Frank DAmelio who outlined expectations for a Q2 pandemic hit followed by a full recovery in the second half of this year highlighted 2 key priorities for capital allocation: dividends and M&A. And right now, the prospects of finding a buyout bargain are better than ever. Stay Well Be Safe, Best


<< Previous
Bullboard Posts
Next >>